Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

PFE 34.16 -0.14 (-0.41%)
price chart
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for ...
Verastem Inks Separate Deals for Wnt and FAK Inhibitors  Genetic Engineering News
Related articles »  
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
Related articles »  
Is Pfizer A Good Buy?
Pfizer has been involved in a series of acquisitions and sell offs, some cheered and some criticized by investors. They recently sold off their nutrition business to Nestle for $11.9 billion.
Pfizer Defends $25 Fair Value With Lyrica Patent Lawsuit Win  Trefis
Related articles »  
Pharmacies Sue Pfizer Over Lipitor
Five retailers joined a legal battle against Pfizer Inc., accusing the drug maker of using anticompetitive tactics to delay the introduction of competing generic copies of Pfizer's blockbuster cholesterol-lowering pill Lipitor.
Retailers sue Pfizer, charge generic Lipitor delay  Inquirer.net
Pfizer sued by retailers for generic Lipitor delay  Fox News
Related articles »  
Why We Think Pfizer Remains Significantly Undervalued
If a company is undervalued both on a DCF and on a relative valuation basis and is showing improvement in technical and momentum indicators, it scores high on our scale.
Related articles »  
Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC ...
Pfizer-J&J Alzheimer's Drug Fails to Aid Cognition  Bloomberg
Hopes dim for Alzheimer's trials after Pfizer failure  Reuters
Related articles »  
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
Considering lack of progress in the RNAi space to date and the fact that the drug, ALN-TTR02, is one the company's biggest pipeline hopes, this makes encouraging news, particularly as a phase II study has already started.
Alnylam Gains on Treatment Data for Deadly Nerve Disease  Bloomberg
Related articles »  
Pfizer's Cost-Cuts Offset Loss of Lipitor
Drug maker Pfizer Inc. reported a 25% increase in second-quarter profit, as lower expenses helped cushion sales erosion from the loss of U.S.
Pfizer IPO, Cost Cuts Yield Time to Reinvent Its Research  Bloomberg
Pfizer 2Q net income rises 25 pct on lower costs  Medical Xpress
Related articles »  
Pfizer Wins Patent Ruling, Exclusive Sales for Lyrica Drug
July 20 (Bloomberg) -- Pfizer Inc., the world's largest drugmaker, convinced a U.S. judge that its patents for the pain-drug Lyrica are valid and infringed, giving it exclusive sales rights until 2018.
Pfizer Wins Lyrica Patent Ruling  Wall Street Journal
Pfizer and Northwestern University Win LYRICA� Patent Case in Delaware ...  Business Wire (press release)
Related articles »  
Travelers Sues Pfizer For $47M Over Epilepsy Drug
Law360, New York (July 18, 2012, 11:09 PM ET) -- Travelers Indemnity Co. and several of its affiliates on Wednesday filed a $47 million suit against Pfizer Inc. claiming they overpaid for epilepsy drug Neurontin because of its anti-competitive efforts ...